Bayer Acquires Full Ownership of Bayer Zydus Pharma Private Limited in India

Bayer Pharmaceuticals acquires remaining 25% stake in Bayer Zydus Pharma Private Limited, a joint venture with Zydus Lifesciences. The acquisition marks a significant milestone in Bayer's commitment to driving sustainable development in India's growing pharmaceutical market.

author-image
Rafia Tasleem
New Update
Bayer Acquires Full Ownership of Bayer Zydus Pharma Private Limited in India

Bayer Acquires Full Ownership of Bayer Zydus Pharma Private Limited in India

Bayer Pharmaceuticals Private Limited has acquired remaining, stake of Bayer Zydus Pharma Private Limited (BZPPL), a joint venture with Zydus Lifesciences Limited (formerly Cadila Healthcare), after 13 years of partnership. The 50:50 joint venture was initially established on January 28, 2011, for the sales and marketing of pharmaceutical products in India.

Why this matters: This acquisition marks a significant milestone in Bayer's commitment to driving sustainable development and generating a positive impact with its businesses in India, which could lead to improved access to innovative healthcare solutions for the country's growing population. This acquisition marks a significant milestone in Bayer's commitment to driving sustainable development and generating a positive impact with its businesses in India, which could lead to improved access to innovative healthcare solutions for the country's growing population. As India's pharmaceutical market continues to expand, this move could have broader implications for the country's healthcare sector and economy.

Over the years, the joint venture successfully leveraged the strengths of both companies to better serve the fast-growing Indian market. BZPPL made remarkable strides in various therapies, including cardiovascular diseases, diabetes, women's health, ophthalmology, and oncology.

Shweta Rai, Managing Director - India and Country Division Head - South Asia, Bayer's Pharmaceuticals division, stated, "Zydus Lifesciences has been a formidable partner in our joint mission towards introducing best-in-class innovative health solutions and addressing the unmet healthcare needs of patients in India. As we assume remaining, stake, secure, full, ownership of BZPPL, Bayer remains committed to ensuring its steadfast presence in India. Building on the gains made over more than a decade, we aim to carry forward our mission of 'Health for All, Hunger for None'."

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. The company's mission is "Health for all, Hunger for none," aiming to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. In fiscal 2023, the Group employed around 100,000 people and had sales of 47.6 billion euros. R&D expenses before special items amounted to 5.8 billion euros.

The acquisition of BZPPL marks a significant milestone in Bayer's commitment to driving sustainable development and generating a positive impact with its businesses in India. With full ownership, Bayer aims to further strengthen its presence in the Indian market and continue to introduce innovative healthcare solutions that address the unmet needs of patients.

India's pharmaceutical market has been growing rapidly in recent years, driven by factors such as increasing healthcare awareness, rising disposable incomes, and a growing middle class. The country's pharmaceutical industry is expected to reach $65 billion by 2024 and $120-130 billion by 2030, according to the article.

Bayer's acquisition of BZPPL reflects the company's confidence in the Indian market and its potential for growth. With full control over the joint venture, Bayer can now leverage its global expertise and resources to further expand its presence in India and tap into the country's growing demand for innovative healthcare solutions.

Key Takeaways

  • Bayer acquires remaining 25% stake in Bayer Zydus Pharma Private Limited.
  • The acquisition marks a milestone in Bayer's commitment to sustainable development in India.
  • Bayer aims to improve access to innovative healthcare solutions for India's growing population.
  • India's pharmaceutical market is expected to reach $65 billion by 2024 and $120-130 billion by 2030.
  • Bayer's acquisition reflects its confidence in the Indian market and its potential for growth.